PE20181921A1 - NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS - Google Patents
NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICASInfo
- Publication number
- PE20181921A1 PE20181921A1 PE2018001974A PE2018001974A PE20181921A1 PE 20181921 A1 PE20181921 A1 PE 20181921A1 PE 2018001974 A PE2018001974 A PE 2018001974A PE 2018001974 A PE2018001974 A PE 2018001974A PE 20181921 A1 PE20181921 A1 PE 20181921A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- new anti
- sirpa
- antibodies
- therapeutic applications
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 abstract 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 101150036449 SIRPA gene Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se refiere a nuevos anticuerpos anti-SIRPa o un fragmento de union a antigeno del mismo que comprende: a) un dominio variable de cadena pesada que comprende HCDR1, HCDR2 y HCDR3 en la secuencia de aminoacidos SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 17 respectivamente y b) un dominio variable de cadena ligera que comprende LCDR1, LCDR2 y LCDR3 en la secuencia de aminoacidos SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23 capaces de antagonizar especificamente la interaccion entre SIRPa y CD47, sin afectar la interaccion entre SIRPg Y CD47. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos anticuerpos son utiles en el tratamiento del cancer inflamatorio, cancer con celulas mieloides infiltradas, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322707P | 2016-04-14 | 2016-04-14 | |
| EP17305182 | 2017-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181921A1 true PE20181921A1 (es) | 2018-12-11 |
Family
ID=58185461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001974A PE20181921A1 (es) | 2016-04-14 | 2017-04-14 | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3443010B1 (es) |
| CN (1) | CN109071664B (es) |
| AU (1) | AU2017248626B2 (es) |
| BR (1) | BR112018070823A2 (es) |
| CA (1) | CA3020373A1 (es) |
| CO (1) | CO2018010855A2 (es) |
| EA (1) | EA201891882A1 (es) |
| PE (1) | PE20181921A1 (es) |
| PT (1) | PT3443010T (es) |
| SG (1) | SG11201808465UA (es) |
| WO (1) | WO2017178653A2 (es) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL256989B (en) | 2015-08-07 | 2022-08-01 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| KR102355240B1 (ko) | 2016-04-14 | 2022-01-25 | 오제 이뮈노테라프틱스 | 신규한 항-SIRPa 항체 및 이들의 치료학적 적용 방법 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| SG10201912879YA (en) | 2016-12-09 | 2020-02-27 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
| JP7179743B2 (ja) * | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| MX2019012233A (es) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anticuerpos anti-sirpa. |
| RU2771174C2 (ru) * | 2017-05-16 | 2022-04-28 | Байондис Б. В. | АНТИ-SIRPα АНТИТЕЛА |
| WO2019027903A1 (en) | 2017-08-02 | 2019-02-07 | Phanes Therapeutics, Inc. | ANTI-CD47 ANTIBODIES AND USES THEREOF |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| WO2019080883A1 (en) * | 2017-10-26 | 2019-05-02 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. | NOVEL RECOMBINANT FUSION PROTEINS, PREPARATION THEREOF AND USE THEREOF |
| BR112020017709A2 (pt) * | 2018-03-13 | 2020-12-29 | Ose Immunotherapeutics | Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos |
| JP7386800B2 (ja) * | 2018-03-14 | 2023-11-27 | メモリアル スローン－ケタリング キャンサー センター | 抗ポリシアル酸抗体およびその使用 |
| CN118344481A (zh) * | 2018-03-21 | 2024-07-16 | Alx肿瘤生物技术公司 | 针对信号调控蛋白α的抗体和使用方法 |
| MA52753A (fr) | 2018-05-25 | 2021-04-21 | Alector Llc | Anticorps anti-sirpa et leurs procédés d'utilisation |
| US12024566B2 (en) * | 2018-07-10 | 2024-07-02 | National University Corporation Kobe University | Anti-SIRPalpha antibody |
| US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| SG11202102851XA (en) * | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| GB2593632B (en) | 2018-10-29 | 2023-05-24 | Umc Utrecht Holding Bv | IGA mediated killing of aberrant cells by CD47-Sirpalpha checkpoint inhibition of neutrophils |
| US11202828B2 (en) * | 2018-11-14 | 2021-12-21 | Arch Oncology, Inc. | Therapeutic SIRP-α antibodies |
| BR112021009275A2 (pt) | 2018-11-15 | 2022-01-04 | Byondis Bv | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. |
| EP3898676A1 (en) * | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
| WO2020176790A1 (en) * | 2019-02-27 | 2020-09-03 | Fred Hutchinson Cancer Research Center | Hydrogel compositions and methods for treatment of malignancies |
| EP3969476A1 (en) * | 2019-03-04 | 2022-03-23 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| WO2020243338A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| WO2020247820A1 (en) | 2019-06-07 | 2020-12-10 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| UA129329C2 (uk) | 2019-06-25 | 2025-03-19 | Гіліад Сайєнсіз, Інк. | ЗЛИТІ БІЛКИ FLT3L-Fc |
| EP3756688A1 (en) | 2019-06-25 | 2020-12-30 | Université de Nantes | Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection |
| US20210347908A1 (en) * | 2019-08-20 | 2021-11-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-sirpa antibodies |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| MX2022006078A (es) | 2019-11-27 | 2022-08-02 | Alx Oncology Inc | Terapias de combinacion para el tratamiento del cancer. |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| CN111116713B (zh) * | 2020-01-07 | 2023-06-23 | 郑州大学 | Sirpa蛋白亲和环肽及其应用 |
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| BR112022017136A2 (pt) | 2020-02-28 | 2022-10-11 | Tallac Therapeutics Inc | Conjugação mediada por transglutaminase |
| PE20230784A1 (es) | 2020-05-19 | 2023-05-11 | Boehringer Ingelheim Int | Moleculas de fijacion para el tratamiento de cancer |
| CA3178157A1 (en) | 2020-06-01 | 2021-12-09 | Jaume Pons | Combination therapies comprising a hypomethylation agent for treating cancer |
| CA3198330A1 (en) | 2020-11-11 | 2022-05-19 | Mayumi SUE | Combination of an antibody-drug conjugate with anti-sirp.alpha. antibody |
| WO2022110922A1 (zh) | 2020-11-30 | 2022-06-02 | 启愈生物技术(上海)有限公司 | 抗SIRPα抗体或其抗原结合片段及应用 |
| JP2023552375A (ja) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| CN117355539A (zh) * | 2021-05-28 | 2024-01-05 | 百奥泰生物制药股份有限公司 | 抗SIRPα抗体及其应用 |
| EP4347653A1 (en) | 2021-06-04 | 2024-04-10 | Boehringer Ingelheim International GmbH | Anti-sirp-alpha antibodies |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022298639B2 (en) | 2021-06-23 | 2024-11-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023013915A (es) | 2021-06-29 | 2024-01-25 | Seagen Inc | Métodos para tratar el cáncer con una combinación de un anticuerpo anti-cd70 no fucosilado y un antagonista de cd47. |
| EP4389767A1 (en) | 2021-08-17 | 2024-06-26 | Hangzhou Jiuyuan Gene Engineering Co., Ltd | Monoclonal antibody targeting sirp? and use thereof |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CR20240173A (es) | 2021-10-29 | 2024-06-20 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2023094698A1 (en) | 2021-11-29 | 2023-06-01 | Ose Immunotherapeutics | Specific antagonist anti-sirpg antibodies |
| EP4452415A1 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| CN119031937A (zh) | 2022-03-24 | 2024-11-26 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的联合疗法 |
| AU2023249523A1 (en) | 2022-04-05 | 2024-10-17 | Gilead Sciences, Inc. | Combinations of antibody therapies for treating colorectal cancer |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| WO2023219072A1 (ja) | 2022-05-10 | 2023-11-16 | 第一三共株式会社 | 抗体－薬物コンジュゲートと抗ＳＩＲＰα抗体の組み合わせ |
| US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN119192379B (zh) * | 2024-11-22 | 2025-01-28 | 四川省医学科学院·四川省人民医院 | 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100215640A1 (en) * | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| CA2702217A1 (en) * | 2007-10-11 | 2009-04-16 | Jayne Danska | Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| CN101780283A (zh) * | 2010-03-16 | 2010-07-21 | 中国人民解放军第二军医大学 | 信号调节蛋白α在制备预防和治疗肿瘤的DC疫苗中的应用 |
| CN101880324B (zh) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用 |
| EP3116544A4 (en) * | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
-
2017
- 2017-04-14 AU AU2017248626A patent/AU2017248626B2/en active Active
- 2017-04-14 BR BR112018070823A patent/BR112018070823A2/pt unknown
- 2017-04-14 PE PE2018001974A patent/PE20181921A1/es unknown
- 2017-04-14 WO PCT/EP2017/059071 patent/WO2017178653A2/en active Application Filing
- 2017-04-14 PT PT177188810T patent/PT3443010T/pt unknown
- 2017-04-14 CA CA3020373A patent/CA3020373A1/en active Pending
- 2017-04-14 EP EP17718881.0A patent/EP3443010B1/en active Active
- 2017-04-14 SG SG11201808465UA patent/SG11201808465UA/en unknown
- 2017-04-14 EA EA201891882A patent/EA201891882A1/ru unknown
- 2017-04-14 CN CN201780023581.2A patent/CN109071664B/zh active Active
-
2018
- 2018-10-10 CO CONC2018/0010855A patent/CO2018010855A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017248626A1 (en) | 2018-10-11 |
| BR112018070823A2 (pt) | 2019-02-05 |
| CO2018010855A2 (es) | 2018-11-13 |
| WO2017178653A3 (en) | 2018-07-05 |
| AU2017248626B2 (en) | 2024-05-09 |
| CN109071664A (zh) | 2018-12-21 |
| CA3020373A1 (en) | 2017-10-19 |
| WO2017178653A2 (en) | 2017-10-19 |
| PT3443010T (pt) | 2024-10-21 |
| SG11201808465UA (en) | 2018-10-30 |
| CN109071664B (zh) | 2023-02-21 |
| EP3443010B1 (en) | 2024-08-07 |
| EA201891882A1 (ru) | 2019-07-31 |
| EP3443010A2 (en) | 2019-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| PE20220218A1 (es) | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion |